Colorectal cancer (CRC) ranks among the leading causes of cancer morbidity and mortality globally, and metastasis to the liver significantly worsens clinical outcomes. The molecular underpinnings that drive liver metastasis have long eluded comprehensive understanding. Through integrated bioinformatics and experimental validation, the Chongqing team exploited high-throughput datasets—GSE41258, GSE68468, and GSE35834—to demonstrate a consistent pattern of markedly reduced OXCT1 expression in liver metastases compared to primary tumors and normal colon tissue. Immunohistochemical analyses further confirmed these findings in patient-derived tissue sections, linking low OXCT1 levels directly to metastatic progression.

Employing sophisticated genetic manipulation techniques, researchers used CRISPR-Cas9 to knockout OXCT1 in colorectal cancer cell lines HCT116 and RKO, which resulted in significantly enhanced migratory capacity of the cells, a hallmark of metastatic potential. Conversely, adenovirus-mediated overexpression of OXCT1 markedly impaired cell migration. These phenotypic changes were not confined to in vitro studies; in vivo models corroborated the tumor-suppressive function of OXCT1, highlighting its vital role in restricting liver colonization by colorectal cancer cells.

Delving into the regulatory mechanisms upstream of OXCT1 expression, the study identified the transcription factor YY1 as a critical modulator. Chromatin immunoprecipitation assays revealed YY1 binding to two discrete promoter regions of the OXCT1 gene (−1191 to −1197 and −1269 to −1275), orchestrating its transcriptional activity. This discovery opens new avenues for intervention at the transcriptional level to modulate OXCT1 expression in CRC.

Transcriptomic sequencing followed by Gene Set Enrichment Analysis (GSEA) pinpointed the Wnt signaling pathway—an oncogenic driver in numerous cancers—as a primary downstream target affected by OXCT1 expression. Overexpression of OXCT1 reduced both the levels and nuclear translocation of CDK8 and beta-catenin, crucial mediators of Wnt signaling. OXCT1 also disrupted the physical interaction between CDK8 and beta-catenin by destabilizing CDK8 and shortening beta-catenin’s half-life, dampening pathway activation. Pharmacological inhibition of CDK8 reversed enhanced migration induced by OXCT1 knockout, whereas CDK8 overexpression abrogated the tumor-suppressive effects of OXCT1, underscoring a finely tuned regulatory axis.

Importantly, the enzymatic activity of OXCT1, particularly mediated by its serine 226 residue, was found indispensable for its tumor-suppressive function. Metabolic analyses revealed that OXCT1 modulates ketone body catabolism, resulting in reduced intracellular acetyl-CoA levels. This metabolic shift leads to decreased histone H3 acetylation, an epigenetic modification essential for transcriptional activation of genes including CDK8. The ensuing downregulation of CDK8 undermines the integrity of the CDK8/beta-catenin complex, culminating in the suppression of oncogenic Wnt signaling and metastatic phenotypes.

Contrastingly, an enzymatic mutant of OXCT1 harboring a serine-to-asparagine substitution at position 226 (S226N) failed to reduce H3 acetylation, impair CDK8/beta-catenin signaling, or inhibit cell migration. This mutation underscored the critical requirement of OXCT1’s enzymatic capacity in mediating its anti-metastatic effects and highlighted the intersection of metabolic enzyme function with epigenetic and signaling regulation in cancer metastasis.

While this study significantly advances the understanding of CRLM pathobiology, the authors acknowledge limitations. The precise mechanisms by which YY1 modulates downstream OXCT1 effects and the broader metabolic rewiring involved remain areas for further investigation. They suggest that comprehensive metabolomic profiling in future studies may illuminate the complex interplay between ketone metabolism and epigenetic regulation in colorectal cancer progression.

In essence, this research delineates a novel metabolic-epigenetic-Wnt signaling axis where OXCT1 acts as a metabolic tumor suppressor, directly influencing the metastatic trajectory of colorectal cancer through modulation of key oncogenic pathways. The identification of the OXCT1/CDK8/beta-catenin axis not only deepens the molecular understanding of liver metastasis but also proposes new therapeutic targets with the potential to mitigate a clinically devastating phenomenon.

The integration of metabolic control and chromatin modification presents a refined paradigm of cancer regulation and highlights the metabolic plasticity cancer cells exploit for progression. Targeting enzymes like OXCT1 to restore their function or modulate associated epigenetic marks offers a promising, multifaceted approach to curb CRC metastasis and improve patient outcomes.

This study positions OXCT1 as a critical biomarker and therapeutic candidate, implicating metabolic pathways in epigenetic reprogramming that converge on oncogenic signaling networks. Such insights pave the way for development of targeted therapies that can disrupt metastatic mechanisms at multiple levels, ultimately providing hope for improved management of colorectal cancer liver metastases.

Subject of Research: Colorectal cancer liver metastasis and molecular regulatory mechanisms involving OXCT1

Article Title: Identification of OXCT1 as a Metabolic Tumor Suppressor of Colorectal Cancer Liver Metastasis via Modulation of the Metabolic-Epigenetic-Wnt Signaling Axis

News Publication Date: Not specified

Web References: http://dx.doi.org/10.1016/j.gendis.2025.101625

Image Credits: Chenhao Li, Deao Gong, Xiaoqun Shan, Kang Wu, Jiayao Yang, Rong Zhang, Ye Huang, Kai Wang, Ni Tang, Yuxi Zhu

Keywords: Colorectal cancer, Acetylation, OXCT1, Liver metastasis, Wnt signaling, CDK8, Beta-catenin, Epigenetics, Ketone metabolism

Colorectal cancer remains one of the leading causes of cancer mortality worldwide, primarily due to its propensity for metastasizing to distant organs, most notably the liver. Despite advances in surgical interventions and systemic therapies, the survival rates for patients with metastatic colorectal cancer remain dismal. This reality underscores a critical urgency for elucidating the mechanisms by which primary colorectal tumors seed distant sites. Alvarez-Villanueva and colleagues ventured into this complex landscape, applying cutting-edge molecular profiling and cellular characterization techniques that have not only mapped but functionally defined a subpopulation of tumor cells bearing hallmarks of metastatic potential.

Central to their discovery is a subpopulation characterized by high expression levels of tight junction proteins and the cell adhesion molecule CDH17 (Cadherin-17). Tight junctions are integral to maintaining epithelial integrity and cell polarity, often disrupted during epithelial-to-mesenchymal transition (EMT), a pivotal process in cancer metastasis. Paradoxically, the research highlights that these metastasis-initiating cells maintain elevated tight junction protein expression, challenging the traditional EMT paradigm that underscores metastatic dissemination as a consequence of junction breakdown and increased cellular motility.

The identification of CDH17 as a marker is particularly novel, given its documented roles in cell-cell adhesion and intestinal epithelial homeostasis. Alvarez-Villanueva’s team demonstrated that CDH17-positive cells within primary colorectal tumors exhibit unique functional properties—enhanced survival, adherence to liver microenvironment constituents, and aggressive colonization capabilities. This population forms a cohesive cluster with maintained intercellular adhesion, suggesting that metastasis may proceed via a collective invasion model rather than by single-cell migration, as previously assumed in many contexts.

Sophisticated in vivo lineage tracing experiments further reinforced these conclusions by showing that liver metastases predominantly originate from this tight junction-high, CDH17-positive population. When selectively ablated or genetically silenced for these markers, the metastatic efficiency was markedly diminished, attesting to their indispensable role in metastatic seeding and outgrowth. This revelation uncovers a potential therapeutic vulnerability, where targeting intercellular adhesion machinery could disrupt metastatic cascade at a fundamental level.

Molecular characterization through single-cell RNA sequencing offered additional insights into the gene expression programs governing these cells. Beyond adhesion molecules, these cells showed enrichment for signaling pathways involved in stemness, survival, and immune evasion, painting a portrait of a highly adapted, resilient tumor cell subtype. Such complexity indicates that these metastasis-initiating cells are not merely phenotypic outliers but possess a multi-faceted biological toolkit optimized for survival in hostile microenvironments.

Intriguingly, the spatial organization of these populations within primary tumors suggested niche-like microenvironments conducive to maintaining their phenotype. The tumor microenvironment, therefore, appears to actively nurture these metastasis-competent cells, opening questions about stromal-tumor interactions and the role of immune components in facilitating metastatic priming.

This research also challenges therapeutic dogma by implicating junctional complexes—traditionally viewed as tumor suppressive—as potential facilitators of malignancy in specific contexts. The clinical implications are profound: treatments aimed indiscriminately at disrupting tight junction integrity might inadvertently promote metastatic dissemination. Clinical trials involving agents targeting adhesion must carefully consider these nuances.

Moreover, the research opens avenues for developing diagnostic biomarkers with prognostic value. Detection of elevated CDH17 and tight junction protein levels in primary colorectal tumors could serve as predictive indicators for liver metastasis risk, enhancing patient stratification and tailoring surveillance protocols accordingly.

From a translational perspective, this discovery prompts renewed enthusiasm for novel drug development focused on modulating cell adhesion molecules or their downstream effectors. Antibodies, small molecules, or even CRISPR-based gene editing techniques might be harnessed to selectively inhibit the metastatic subset without compromising normal tissue integrity.

Furthermore, this study adds to the growing body of evidence that cancer metastasis is a highly regulated process dependent on cellular subpopulations with distinct phenotypic and molecular traits rather than random dissemination. Such refined understanding elevates the conceptual framework guiding research in oncology, moving toward more sophisticated models that incorporate cellular hierarchies and interactive tumor ecosystems.

These groundbreaking insights contribute to a broader narrative emphasizing the need to dissect tumor heterogeneity not only at the genetic but also at the functional and spatial levels. The integration of multi-omics datasets with advanced imaging and in vivo models positions research at a cusp of discovery, where targeted interventions might finally stem the lethal tide of metastatic colorectal cancer.

As the oncology community digests these findings, the hope is that clinical translation follows swiftly. Personalized medicine approaches could integrate these molecular markers into clinical workflows, refining therapeutic strategies to intercept metastasis before it manifests clinically.

Future research directions, as the study suggests, include exploring the interaction dynamics between CDH17-positive cell populations and the hepatic microenvironment, the immune landscape modulation during metastatic colonization, and the potential plasticity of these cells under therapeutic pressure.

In sum, Alvarez-Villanueva et al.’s study breaks new ground by pinpointing a clearly defined, adhesion-rich cellular source driving colorectal liver metastases. Challenging existing assumptions about EMT and metastasis, their work invites a paradigm shift in how scientists and clinicians approach one of oncology’s toughest challenges, promising a future where metastatic disease might be anticipated, intercepted, and ultimately conquered through targeted molecular intervention.

Subject of Research: Cellular mechanisms and molecular identity of colorectal cancer cells responsible for liver metastases.

Article Title: Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases.

Article References:
Alvarez-Villanueva, D., Maqueda, M., Harti, D. et al. Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases. Nat Commun (2026). https://doi.org/10.1038/s41467-025-68169-3

Image Credits: AI Generated

Human prostate cancer samples exhibiting perineural invasion—a condition where cancer cells encroach upon or surround nerves—displayed a significantly elevated mitochondrial load within cancer cells proximal to nerves. Using high-throughput multispectral imaging coupled with machine learning algorithms, researchers quantified mitochondrial abundance across tens of thousands of cells. Their precise spatial analysis revealed that cancer cells neighboring nerves harbored considerably more mitochondria than their distant counterparts, suggesting a nerve-dependent metabolic advantage in these cancer cells.

To further dissect whether this phenomenon involved actual mitochondrial transfer rather than mere mitochondrial biogenesis within cancer cells, the research team leveraged a clinical trial involving chemical denervation of the human prostate using botulinum neurotoxin A (BoNT/A). This intervention selectively reduced neuronal activity at the tumor site, serving as a natural experiment to observe the influence of neuronal innervation on cancer mitochondrial content. Remarkably, cancer cells on the denervated side exhibited a stark reduction in mitochondrial load, directly linking neuronal presence to mitochondrial enrichment in tumor cells and strongly implying transfer of mitochondria from nerves to cancer.

To substantiate these findings with robust in vivo models, the researchers employed a BALB/c mouse xenograft system, where murine dorsal root ganglion (DRG) neurons innervating the mammary fat pad were genetically modified to express a mitochondria-targeted green fluorescent protein (GFP) reporter under the synapsin-1 promoter, allowing for neuron-specific mitochondrial labeling. Following the injection of 4T1 breast cancer cells tagged with a red fluorescent protein (mCherry) into the same fat pad, analysis of emerging tumors by flow cytometry detected a distinct subpopulation of cancer cells emitting the GFP mitochondrial signal. This provided compelling evidence that mouse host neurons transferred mitochondria directly into malignant cells within the tumor microenvironment.

Notably, this transfer was shown to be specific to mitochondria, as a control lentiviral construct encoding a nucleus-localized GFP failed to show any signal exchange, ruling out nonspecific protein transfer or artifact. This elegant genetic design confirmed that intact mitochondria, rather than soluble proteins or other organelles, crossed from host neurons into cancer cells in situ, emphasizing the precision and selectivity of this intercellular communication.

Beyond imaging and fluorescence-based assays, the team implemented advanced genetic approaches to detect mitochondrial DNA (mtDNA) transfer at the molecular level. By identifying distinct mtDNA polymorphisms inherent to the host mouse strain and the transplanted cancer cells through Sanger sequencing, they established a unique molecular signature. Cancer cells recovered from tumors via fluorescence-activated cell sorting (FACS) underwent deep Oxford Nanopore sequencing to detect the presence of host-derived mtDNA within the tumor cell population. The results definitively demonstrated heteroplasmy—cancer cells contained a mixture of their own and neuron-derived mtDNA—validating that mitochondrial transfer is not merely a superficial event but involves functional genetic material.

Importantly, denervation via BoNT/A treatment in the xenograft model resulted in a significant decrease of approximately 35% in the mitochondrial transfer events from neurons to cancer cells. This implies that neural activity and integrity are key drivers of mitochondrial donation, and that interfering with nerve presence or function may modulate tumor metabolism and progression by denying cancer cells this mitochondrial influx.

The implications of nerve-to-cancer mitochondrial transfer are profound, as mitochondria are central to energy production, metabolic adaptation, and apoptotic regulation. Mitochondrial acquisition by cancer cells could endow them with enhanced bioenergetic capacity, resistance to metabolic stress, and even influence metastatic potential. This discovery adds a new dimension to tumor–nerve interactions, previously focused largely on growth factor secretion and neurotransmitter release, by highlighting organelle-level communication.

From a therapeutic standpoint, these findings suggest new intervention points. Chemical denervation or strategies to block mitochondrial transfer mechanisms may disrupt this symbiotic relationship, potentially depriving cancer cells of vital metabolic support and hindering tumor growth and metastasis. Furthermore, the use of neuron-specific mitochondrial reporters in preclinical models paves the way for real-time imaging and therapeutic monitoring in future studies.

The researchers’ methodical approach, combining clinical patient sample analysis, advanced imaging platforms, genetic manipulation, and rigorous sequencing, exemplifies the power of multidisciplinary strategies in unraveling complex cellular communications. Their use of machine learning for image quantification allowed unprecedented cellular resolution and statistical power to detect subtle spatial mitochondrial variations linked to nervous system presence.

As cancer research continues to unravel the tumor microenvironment’s multifaceted influencers, the role of nerves emerges as a critical, active participant rather than a mere passive structure. The revelation that neurons can donate mitochondria to cancer cells during metastasis challenges classical tumor biology and invites new perspectives on tumor–neuron crosstalk.

Future research will need to clarify the precise molecular machinery mediating mitochondrial transfer, such as tunneling nanotubes, extracellular vesicles, or synaptic-like junctions, and how these processes are regulated by the tumor microenvironment. Understanding the downstream metabolic and signaling consequences of mitochondrial acquisition on cancer cell behavior will be equally critical.

In sum, this pioneering study illuminates a novel biological axis in cancer metastasis—the nerve-to-cancer mitochondrial conduit—adding an organelle-centric lens to investigate tumor progression and offering novel targets for therapeutic innovation. As interdisciplinary efforts converge, exploiting neural physiology to impede cancer’s metabolic support systems may forge new frontiers in oncology.

Subject of Research: Mitochondrial transfer from nerves to cancer cells during cancer metastasis

Article Title: Nerve-to-cancer transfer of mitochondria during cancer metastasis

Article References:
Hoover, G., Gilbert, S., Curley, O. et al. Nerve-to-cancer transfer of mitochondria during cancer metastasis. Nature (2025). https://doi.org/10.1038/s41586-025-09176-8